However, a randomized, double-blind, and placebo-compared clinical examination demonstrated that the PFE cure does not delay the PSADT in PCa patients with increment PSA following the primary remedy compared to the placebo-controlled group [13]. Here, KLK3 is linked to posterior cortical atrophy.